Cargando…

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

BACKGROUND: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. METHODS: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered...

Descripción completa

Detalles Bibliográficos
Autores principales: Zohrabi, Ilnaz, Abedi, Parvin, Ansari, Somayeh, Maraghi, Elham, Shakiba Maram, Nader, Houshmand, Gholamreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236919/
https://www.ncbi.nlm.nih.gov/pubmed/32429977
http://dx.doi.org/10.1186/s12905-020-00935-5
_version_ 1783536230835683328
author Zohrabi, Ilnaz
Abedi, Parvin
Ansari, Somayeh
Maraghi, Elham
Shakiba Maram, Nader
Houshmand, Gholamreza
author_facet Zohrabi, Ilnaz
Abedi, Parvin
Ansari, Somayeh
Maraghi, Elham
Shakiba Maram, Nader
Houshmand, Gholamreza
author_sort Zohrabi, Ilnaz
collection PubMed
description BACKGROUND: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. METHODS: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40–60, at least 1 year passed from their last menstrual period or the level of FSH > 40 IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention. RESULTS: The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7 ± 7.18 vs. 3.69 ± 2.76, p = 0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76 ± 4.68 to 52.48 ± 7.54) in comparison to the placebo group (increased from 8.58 ± 4.35 to 13.25 ± 5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p = 0.0001). After 8 weeks, 88.6 and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p = 0.001). CONCLUSION: The results of this study showed that eight- week intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended. TRIAL REGISTRATION: IRCT20160602028220N2.
format Online
Article
Text
id pubmed-7236919
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72369192020-05-27 The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial Zohrabi, Ilnaz Abedi, Parvin Ansari, Somayeh Maraghi, Elham Shakiba Maram, Nader Houshmand, Gholamreza BMC Womens Health Research Article BACKGROUND: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. METHODS: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40–60, at least 1 year passed from their last menstrual period or the level of FSH > 40 IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention. RESULTS: The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7 ± 7.18 vs. 3.69 ± 2.76, p = 0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76 ± 4.68 to 52.48 ± 7.54) in comparison to the placebo group (increased from 8.58 ± 4.35 to 13.25 ± 5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p = 0.0001). After 8 weeks, 88.6 and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p = 0.001). CONCLUSION: The results of this study showed that eight- week intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended. TRIAL REGISTRATION: IRCT20160602028220N2. BioMed Central 2020-05-19 /pmc/articles/PMC7236919/ /pubmed/32429977 http://dx.doi.org/10.1186/s12905-020-00935-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zohrabi, Ilnaz
Abedi, Parvin
Ansari, Somayeh
Maraghi, Elham
Shakiba Maram, Nader
Houshmand, Gholamreza
The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
title The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
title_full The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
title_fullStr The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
title_full_unstemmed The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
title_short The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
title_sort effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236919/
https://www.ncbi.nlm.nih.gov/pubmed/32429977
http://dx.doi.org/10.1186/s12905-020-00935-5
work_keys_str_mv AT zohrabiilnaz theeffectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT abediparvin theeffectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT ansarisomayeh theeffectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT maraghielham theeffectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT shakibamaramnader theeffectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT houshmandgholamreza theeffectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT zohrabiilnaz effectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT abediparvin effectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT ansarisomayeh effectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT maraghielham effectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT shakibamaramnader effectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial
AT houshmandgholamreza effectofoxytocinvaginalgelonvaginalatrophyinpostmenopausalwomenarandomizedcontrolledtrial